Sirnaomics becoming a Constituent of Hang Seng Family of Indexes
The board (the “Board”) of directors (the “Directors”) of Sirnaomics Ltd. (the “Company”) is pleased to announce that the Company has been selected as a constituent stock of the following index series by Hang Seng Indexes Company Limited, with effect from September 5, 2022:
(1) Hang Seng Composite Index (“HSCI”);
(2) Hang Seng Stock Connect Hong Kong Index (“HSHKI”);
(3) Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index;
(4) Hang Seng Stock Connect Hong Kong SmallCap Index;
(5) Hang Seng SCHK Mainland China Companies Index;
(6) Hang Seng SCHK ex-AH Companies Index;
(7) Hang Seng Healthcare Index; and
(8) Hang Seng Small Cap (Investable) Index.
HSCI offers a comprehensive Hong Kong market benchmark that covers about the top 95th percentile of the total market capitalization of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited. HSCI can be used as a basis for index funds, mutual funds as well as performance benchmarks, and assists international and local investors in formulating investment strategies. Inclusion into the HSCI will allow the Company’s stock to be eligible for trading on the Hong Kong Stock Connect, a channel for stock trading between investors in Hong Kong and those in mainland China. HSHKI serves as a benchmark to reflect the overall performance of the securities listed in Hong Kong that are eligible for trading via the southbound trading link of Stock Connect. It covers equities eligible for trading via such scheme, with additional liquidity screening to make the covered equities a more investable reference set for mainland China investors.
The Board is of the view that the selection of the Company as a constituent stock of the abovementioned index series of Hang Seng Indexes Company Limited is expected to be conducive in introducing more diversified investors for the Company, improving stock liquidity and promoting the Company’s reputation in the capital market. The Company will continuously devote to the exploration and development of RNAi therapeutics to bring benefits to patients and create value for its shareholders.
Please visit the website of Hang Seng Indexes Company Limited (http://www.hsi.com.hk) for the relevant index notice.